Cell Treatment Slows Disease in Duchenne Muscular Dystrophy Patients

18th April, 2022

22 April 2022, News of the Week, Newsletter

[Source: Science Daily]

A cell therapy developed by the executive director of the Smidt Heart Institute stabilizes weakened muscles-including the heart muscle-in Duchenne muscular dystrophy patients, a new study published in the international peer-reviewed journal The Lancet shows.

If the HOPE-2 study’s success is duplicated in the upcoming multicenter, randomized, placebo-controlled HOPE-3 clinical trial, the intravenous cell therapy could become the first Food and Drug Administration-approved treatment for Duchenne patients with advanced disease.

Read the Rest of this Article on Science Daily

PediaStaff is Hiring!

All Jobs

PediaStaff hires pediatric and school-based professionals nationwide for contract assignments of 2 to 12 months. We also help clinics, hospitals, schools, and home health agencies to find and hire these professionals directly. We work with Speech-Language Pathologists, Occupational and Physical Therapists, School Psychologists, and others in pediatric therapy and education.